Monoclonal Antibodies Targeting SARS-VOC-2 Nucleocapsid Protein

At a Glance

Researchers at Colorado State University have developed and characterized a panel of monoclonal antibodies targeting the SARS-CoV-2 nucleocapsid protein.  The clones were tested for activity in western blots, ELISAs, and immunofluorescence assays with SARS-CoV-2 infected cells and for cross reactivity against SARS-CoV, HuCoV-NL63, and HuCoV-229E N protein. Overall, data provides a strong foundation for the use of the monoclonal antibodies to study SARS-CoV-2 N protein and development of novel diagnostic assays to detection of COVID-19.

Background

Coronavirus nucleocapsid protein plays a key role in coating the viral RNA genome during virion formation, and overall pathogenesis. Additionally, the nucleocapsid protein has been used as a diagnostic marker for active coronavirus infection. There are very few antibody reagents currently available that are specific for SARS-CoV-2 nucleocapsid, as most monoclonal antibodies that are commercially available were generated against SARS-CoV nucleocapsid protein and are cross-reactive for SARS-CoV-2 nucleocapsid. There is a significant need for new antibodies to be produced with increased specificity and utility for detecting SARS-CoV-2 nucleocapsid protein for both the research community and the necessity to develop therapeutics.

Benefits

  • Antibodies specifically target SARS-CoV-2 nucleocapsid
  • Nucleocapsid protein is a diagnostic marker for active coronavirus infection
  • Application in ELISA assays, reducing/denatured western blots, immunofluorescence assays, sandwich ELISAs, gene sequences, and others
Last Updated: January 2024
Test tube for COVID-19
Opportunity

Available for Non-Exclusive License
Available for Collaboration

Inventors

Brian Geiss
Tony Schountz
James Terry

Reference Number
2020-109
Licensing Manager

Steve Foster
Steve.Foster@colostate.edu
970-491-7100